News Channels

11 Jun 2017 Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS
11 Jun 2017 Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
11 Jun 2017 Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
11 Jun 2017 NewLink Genetics to Regain Rights to GDC-0919
09 Jun 2017 Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer
08 Jun 2017 Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
08 Jun 2017 Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
07 Jun 2017 Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
07 Jun 2017 Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates with Improved Microbiome Diversity
07 Jun 2017 InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)
07 Jun 2017 Menarini Expands its Capabilities for Antibody Drug Conjugate (ADC) Projects
07 Jun 2017 Avanir Pharmaceuticals Initiates Phase II Study to Evaluate AVP-786 for Treatment of Neurobehavioral Disinhibition Associated with Traumatic Brain Injury
07 Jun 2017 TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress
07 Jun 2017 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention
07 Jun 2017 Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum Βeta-lactamase Inhibitor, at ASM Microbe 2017
07 Jun 2017 Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer
07 Jun 2017 Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
07 Jun 2017 Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
07 Jun 2017 ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
07 Jun 2017 AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing